Search

Objective: To investigate the value of 99mTc-MIBI myocardial perfusion tomography monitoring the cardiotoxicity induced by anthracycline., Methods: Twenty-three patients with anthracycline chemotherapy were examined by electrocardiogram (ECG), myocardial enzyme (CK-MB), nuclear angiography for detecting left ventricular ejection fraction (LVEF) and 99mTc-MIBI myocardial perfusion tomography for detecting myocardial relative quantity (MRQ). These examinations were repeated after every chemotherapy., Results: The MRQ after one period of anthracycline chemotherapy was significantly lower than the pretherapy in 23 patients (P < 0.01). The MRQ significantly decreased after one period of chemotherapy in 11 patients treated by pirarubicin, in 6 by epirubicin, and 6 by mitoxantrone (P < 0.05). There was not significant change in the mean value of ECG and CK-MB after one period of chemotherapy (P > 0.05). After multiple-period anthracycline chemotherapy in 10 patients, a decrease was observed in MRQ (P < 0.01). There was not significant difference in MRQ between multiple periods and one period therapy (P > 0.05) and in LVEF in the period before and after multiple-period chemotherapy (P > 0.05)., Conclusion: 99mTc-MIBI myocardial perfusion tomography can monitor the anthracycline cardiotoxicity and its changes are earlier than LVEF's. 99mTC-MIBI myocardial perfusion tomography may be helpful to the clinical treatment for anthracycline.

Objective: To investigate the relationship between the axially lymph nodes metastases and the bone metastases in patients with the breast cancer., Methods: Lymphadenotomy of the axially lymph nodes had been performed on patients with the breast cancer, and the excised axially lymph nodes were observed by pathological examination. All patients underwent postoperatively total bone scan with single photon emission computer tomography (SPECT) periodically., Results: Among 292 patients with the breast cancer, the bone metastatic rates of low and high differentiating tumor were 27.3% (6/22) and 45.2% (122/272) respectively, the bone metastatic rates in both tumors had no difference (P > 0.1). The bone metastatic rate was 54.3% (100/184) in patients suffered from the axially lymph nodes metastases, and 25.9% (28/108) in non-metastases patients respectively, the difference of their bone metastatic rates was significant (P < 0.001). The bone metastatic rate was 48.4% (62/128) in patients suffered from the metastases of axially lymph nodes after operation less 2 years, and 67.8% (38/56) after operation more than 2 years respectively, the difference of their bone metastatic rates was not significant (P < 0.5)., Conclusions: There is no relationship between the bone matastatic rates and the pathological type of tumor. The bone metastatic rates of patients with the axially lymph nodes metastases are higher than those with non-metastases of axially lymph nodes. In addition, the bone metastatic rates of patients with the axially lymph nodes metastases increase with time prolongation.